Soleno Therapeutics, Inc. (SLNO) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 9 Buy, 4 Hold.
The consensus price target is $95.25 (low: $60.00, high: $114.00), representing an upside of 81% from the current price $52.62.
Analysts estimate Earnings Per Share (EPS) of $-3.89 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.38 vs est $-3.89 (missed -12.6%). 2025: actual $0.41 vs est $0.29 (beat +39.9%). Analyst accuracy: 80%.
SLNO Stock — 12-Month Price Forecast
$95.25
▲ +81.01% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Soleno Therapeutics, Inc., the average price target is $95.25, with a high forecast of $114.00, and a low forecast of $60.00.
The average price target represents a +81.01% change from the last price of $52.62.
Highest Price Target
$114.00
Average Price Target
$95.25
Lowest Price Target
$60.00
SLNO Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Soleno Therapeutics, Inc. in the past 3 months
EPS Estimates — SLNO
80%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.38
vs Est –$3.89
▼ 11.2% off
2025
Actual $0.41
vs Est $0.29
▲ 28.5% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — SLNO
98%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2025
Actual $0.190B
vs Est $0.187B
▲ 1.5% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
